SUVN D4010

Drug Profile

SUVN D4010

Alternative Names: SUVN-D4010

Latest Information Update: 17 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Suven Life Sciences
  • Class Antidementias; Antipsychotics
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Alzheimer's disease; Schizophrenia

Most Recent Events

  • 06 Jul 2018 Suven Life Sciences has patent protection for selective 5-HT4 compounds for the treatment of cognitive impairment associated with neurodegenerative disorders in India, Singapore, South Korea and Israel
  • 09 May 2018 Suven Life Sciences has patent protection for serotonin 4 receptor agonists, including SUVN D4010, in Australia, Eurasia and Europe
  • 03 Apr 2018 Suven Life Sciences has patent protection for 5-HT4 compounds in Canada for neurodegenerative disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top